Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00280514|
Recruitment Status : Completed
First Posted : January 23, 2006
Last Update Posted : August 4, 2010
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Abscess Cysts||Drug: cefpirome and moxifloxacin administration||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Official Title:||Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||December 2009|
- ratios of AUC and Cav(ss) to MIC
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 90 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Female or male, aged between 18 and 90 years.
- Written informed consent.
- Abscess formation or abdominal cyst scheduled to drainage.
- Plasma creatinine <1.5 mg/dL
- Pregnancy or lactation.
- Hemodialysis or hemofiltration
- Allergy or hypersensitivity against study drugs
- Massive edemata or hypernatremia
- Reduced liver function (Child-Pugh A, B, C)
- Relevant prolongation of QT-interval
- CNS-diseases which predispose for cramps
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00280514
|Medical University Vienna|
|Vienna, Austria, 1090|
|Principal Investigator:||Johannes Pleiner, MD||Medical University of Vienna, Dep. of Clinical Pharmacology|
|Responsible Party:||Markus Müller, Medical University of Vienna|
|Other Study ID Numbers:||
EUdraCT no. 2005-004455-35
|First Posted:||January 23, 2006 Key Record Dates|
|Last Update Posted:||August 4, 2010|
|Last Verified:||November 2005|
Topoisomerase II Inhibitors
Molecular Mechanisms of Pharmacological Action